‘Striking’ Colon Cancer Data Spur Mid-Presentation Ovation at ESMO
PARIS -- Nearly every single patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a…
Browsing Tag
ESMO
NuCana Presents Promising Data on NUC-7738 at the European Society of Medical…
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pembrolizumab to be…
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative…
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and…
Phoenix, AZ, Sept. 10, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced today initial results from a Phase 0 clinical trial of pamiparib in…
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating…
– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA…
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose…
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of…
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody,…
SAN CARLOS, Calif., Sept. 10, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the…
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety,…
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in…
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR…
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a…
Predicine to Present New Data at ESMO 2022 Demonstrating the Utility of its Portfolio…
SILICON VALLEY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference…